0
variable(s) selected download| Category | Variable name | variable label (+ explanatory notes) | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patient data | gebdat | Date of birth | ||||||||||||||||||||||||||||||||
| Patient data | gesl | Sex |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | iacr | Counts following IACR rules for reporting incidence |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | incdat | Incidence date
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||
| Patient data | incjr | Year of incidence
+
The incidence date is the date of the first histological or cytological confirmation of the tumour. It cannot be later than the start of treatment. If treatment begins before histological confirmation, the incidence date is the date of clinical diagnosis. It must always fall within three months of the first clinical visit related to this tumour.
|
||||||||||||||||||||||||||||||||
| Patient data | ink_ses | Median income in postal code area as a proxy for socioeconomic status (SES)
+
Available from 2010. Socioeconomic status (SES) reflects an individual's social position, which strongly influences health and is linked to life expectancy in good health. Research on SES and health typically uses indicators such as education, income, occupation, and material wealth. This variable uses income as a proxy for SES.
Income data by postal code area were obtained from Statistics Netherlands (CBS), with 2019 as the reference year, downloaded on 16 October 2023 via https://www.cbs.nl/nl-nl/dossier/nederland-regionaal/geografische-data
/gegevens-per-postcode.
Income is defined as the median disposable household income, adjusted for household size and composition. For each area, the median standardised household income was compared to the national distribution and classified into one of five groups: low, lower-middle, middle, upper-middle, or high. Income thresholds (in euros) are available at: https://www.cbs.nl/nl-nl/longread/diversen/2023/statistische-gegevens-per-vierkant-en-postcode-2022-2021-2020-2019/4-beschrijving-cijfers. Because postal code areas often have few households, CBS also
considered the 99% confidence interval of the median income. If this interval spans multiple groups, a new category was created to reflect the range (e.g., 'low to lower-middle'). Categories may partially overlap due to this approach. If the median income is based on fewer than 10 households, it is classified as 'unclassifiable'. CBS originally defined 12 income categories.
For this variable, these were reduced to three to simplify analysis and remove overlaps.
Key considerations:
- Income is a snapshot and does not reflect accumulated wealth.
- Data are aggregated by postal code area, which may include substantial variation.
- Household income is strongly age-dependent; analyses should compare individuals within the same age group.
- Median disposable income is considered valid for up to 10 years before and after the reference year (2019).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | leeft | Age at incidence date | ||||||||||||||||||||||||||||||||
| Patient data | mal | Previous or subsequent malignancies
+
Selection of malignancies to specify in the request:
-Period: Previous and/or subsequent malignancies, or based on a defined timeframe before or around the incidence date.
-Type: All cancer types in the NCR, or all malignant/invasive (excluding skin BCC), or a selection of specific tumour types.
NKR database content with full availability:
Period: Nationwide complete from 1989.
Exclusion criteria:
- Patients residing abroad at the time of incidence
- Basal cell carcinomas of skin and lip
- Second primary invasive and second non-invasive squamous cell carcinomas of the skin
- Adenocarcinoma in situ/high-grade dysplasia of colon, rectosigmoid and rectum
- Carcinoma in situ of the cervix
- Benign/borderline tumours, except: CNS tumours from 2001, Borderline ovarian tumours, AL amyloidosis from 2017, Polymorphic PTLD
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Patient data | mal_incdat | Incidence date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||
| Patient data | mal_int | Interval between incidence date and date of previous or subsequent malignancy | ||||||||||||||||||||||||||||||||
| Patient data | mal_tumsoort | Tumour type of previous or subsequent malignancy
+
Refers to the NCR tumour classification based on site, morphology, and behaviour. For more information, see: https://iknl.nl/nkr/registratie/tumorindeling
|
||||||||||||||||||||||||||||||||
| Patient data | ovldat | Date of death | ||||||||||||||||||||||||||||||||
| Patient data | post_cijf | Numeric part of the patient's postal code at the time of incidence | ||||||||||||||||||||||||||||||||
| Patient data | vit_stat_dat | Date of vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||
| Patient data | vit_stat_int | Interval between incidence date and date of vital status (days)
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
||||||||||||||||||||||||||||||||
| Patient data | vit_stat | Vital status
+
Once a year, at the end of the first quarter, the NCR is linked to the Municipal Personal Records Database (GBA). The GBA is complete up to February of that year. Vital status reflects the status up to this date. For patients listed as alive in the GBA, the vital status date is the date up to which the GBA is complete. If a patient is recorded as deceased or emigrated, the vital status date is the date of death or emigration. Using this date and the incidence date, the interval between incidence and vital status (in days) is calculated.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | topo | Topography excluding sublocation
+
Location of the primary tumour according to ICD-O-3.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | topo_sublok | Topography including sublocation
+
Location and sublocation of the primary tumour according to ICD-O-3.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Tumour data | morf | Morphology
+
Histological type of the tumour (first four digits of the ICD-O morphology code) according to ICD-O-3.2.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Tumour data | morf_cat | Morphology (categories) |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | gedrag | Behaviour
+
Tumour behaviour (fifth digit of the ICD-O morphology code).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | diffgrad | (Differentiation) grade
+
Tumour differentiation grade (sixth digit of the ICD-O morphology code)
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ct | cT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cn | cN (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cm | cM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pt | pT (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pn | pN (TNM)
+
The TNM classification uses the edition applicable at the time of incidence.
Meaning of the last character in pN:
S: Result based only on sentinel node examination (sn)
I: Isolated tumour cells (ITC)
M: Micrometastases (mi)
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pm | pM (TNM)
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2021 for cervical carcinomas
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | cstadium | Clinical TNM stage
+
cstadium: The clinical stage is based on cTNM, which is derived from information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0. Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM. Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | pstadium | Pathological TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
pstadium: The pathological (post-surgical) stage is based on pT, pN and pM. Also in case of pre-surgical therapy, pT and pN are used (ypT and ypN). When no tumour is detectable after pre-surgical therapy, this is shown as pstadium=0.
pM: Indicates whether there is pathological confirmation of distant metastases. There may be distant metastases that are not pathologically confirmed, which are therefore not included in the calculation for this variable.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | stadium | TNM stage
+
The TNM classification uses the edition (UICC) valid at the time of incidence:
1989-1992: 4th edition (TNM 4)
1993-1998: 4th edition, 2nd revision (TNM 4)
1999-2002: 5th edition (TNM 5)
2003-2009: 6th edition (TNM 6)
2010-2016: 7th edition (TNM 7)
2017-2025: 8th edition (TNM 8)
From 2026 onwards: 9th edition (TNM 9)
Exceptions:
TNM 9 from 2025 for carcinomas of the lung, nasopharynx, minor salivary glands and parathyroid gland, and for pleural mesothelioma and paraganglioma/pheochromocytoma
Stadium: Based on pTNM supplemented by cTNM to best reflect the actual stage at diagnosis. Priority is given to pTNM values. If surgery did not occur, pTNM is unknown, or pre-surgical therapy was given (pTNM becomes ypTNM), cTNM values are used.
Meaning of "X" (unknown): Stage cannot be calculated, e.g., TX/NX/M0.
Meaning of "M" (missing): Indicates TNM not recorded, possibly due to incomplete registration or use of EoD staging instead of TNM.
Meaning of "NVT" (not applicable): TNM staging does not apply to this tumour type for the given incidence period.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ond_lymf | Number of regional lymph nodes examined
+
All lymph nodes examined as part of initial diagnostics and treatment combined.
|
||||||||||||||||||||||||||||||||
| Tumour data | pos_lymf | Number of positive regional lymph nodes | ||||||||||||||||||||||||||||||||
| Tumour data | diag_basis | Basis for diagnosis
+
Non-microscopic confirmation:
0 = death certificate only
1 = clinical examination only (medical history and physical)
2 = clinical diagnostic tests, exploratory surgery or autopsy (without microscopic confirmation)
4 = specific biochemical and/or immunological laboratory tests.
Microscopic confirmation:
5 = haematological (bone marrow cytology, e.g., bone marrow aspiration, blood smear) or cytological confirmation of primary tumour or metastases, or definite microscopic confirmation but unclear whether cytology or histology
6 = histological confirmation of metastases only, including at autopsy
7 = histological confirmation of primary tumour, or unclear whether histology refers to primary tumour or
metastasis, including autopsy with histology.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | anorect_overg_afst | Distance to the anorectal junction
+
Recorded for rectal and rectosigmoid carcinomas from 2017 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | anus_afst | Distance to the anus
+
Recorded for rectal carcinomas in the period 2009-2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | braf_mut | BRAF mutation
+
Covers all mutations, not only V600E. BRAF mutation status may be determined at different stages of the treatment pathway (first or later line). Molecular data in the NCR are incomplete, as molecular testing is not performed routinely. In addition, follow-up is not yet systematically recorded for all patients. Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | dubbeltum | Synchronous double tumour present
+
Dual tumours are tumours diagnosed within six months (183 days) of each other. In the NCR, these are recorded under 'Multifocality' if the tumours were removed during the same operation and share the same topography (subsite may differ), or if a dual tumour is not treated surgically. In all other cases, separate registrations are created for each tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | emi | Extramural invasion
+
Available from 2018 onwards for rectal carcinoma and rectosigmoid carcinoma. From 2020 onwards, available for rectal carcinoma only. Applicable only to cT3 tumours.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | gesteelde_poliep | Pedunculated polyp present
+
Available from 2019 for T1 tumours (cT1 and/or pT1) treated with local resection. From 2020 onwards, this also includes T1 tumours treated with surgical resection.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ileus | Presence of ileus at presentation of the primary tumour
+
Available from 2015 to 2019.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | lymf_invas | Lymphatic invasion
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_incdat | Incidence date of metastasis | ||||||||||||||||||||||||||||||||
| Tumour data | meta_int | Interval between incidence date and date of metastasis (days)
+
The incidence date is defined as the date of the first histological or
cytological confirmation of the primary tumour.
The metastasis date refers to the first histological or cytological confirmation of the
metastasis. If histological confirmation does not occur within three
months, the clinical diagnosis date is used. Consequently, the
metastasis date may precede the primary tumour incidence date by up
to three months.
|
||||||||||||||||||||||||||||||||
| Tumour data | meta_topo_sublok | Topography including sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_topo | Topography excluding sublocation of metastasis
+
Metastasis location according to ICD-O-3. Metastatic sites have been recorded nationwide since 2008. For distant metastases at more than three sites, C768 was coded up to 2014 to indicate more than three locations. In 2017/2018 C768 may indicate more than four locations.
Explanation for records where both cM and pM show no metastases despite metastatic sites being recorded at diagnosis: cTNM is based on information available before (neo-adjuvant) treatment, including findings during surgery (if not treated neo-adjuvantly) that influence the treatment plan. pM indicates whether pathological
confirmation exists for distant metastases. If metastases are detected during or after neo-adjuvant treatment, TNM is not updated, but metastasis locations are recorded.
If the dataset includes metastasis locations after progression: only new or enlarged metastases are recorded, not all existing ones. C809 is coded for clinical progression when the site is unknown.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_lever_aantal | Number of liver metastases
+
Available from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_lever_afm | Maximum size of liver metastasis (mm)
+
Available from 2016.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_diag_basis | Basis for metastasis diagnosis |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_lever | Liver metastasis/metastases present
+
Available since 2007.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_long | Lung metastasis/metastases present
+
Available since 2007.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | meta_perit | Peritoneal metastasis/metastases present
+
Available since 2007.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | mrf_afst | Distance to the mesorectal fascia (mm)
+
Available from 2015 for cT2 and cT3 tumours. This refers to the distance between the primary tumour and the MRF, not the distance of any lymph node to the MRF.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | msi_stat | MSI status
+
MSI status may be determined at different stages of the treatment pathway (first or later line). Molecular data in the NCR are incomplete, as molecular testing is not routinely performed. In addition, follow-up is not yet systematically recorded for all patients. Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | perforatie | Perforation present
+
Available from 2015 to 2019.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | poliep_afm | Polyp size (mm)
+
Available from 2019 through 2023. Size is based on the diameter of the polyp. From 2019 onwards for T1 tumours (cT1 and/or pT1) treated with local resection, and since 2020 also for T1 tumours treated with surgical resection.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ras_mut | RAS mutation
+
RAS mutation status may be determined at different stages of the treatment pathway (first or later line). Molecular data in the NCR are incomplete, as molecular testing is not routinely performed. In addition, follow-up is not yet systematically recorded for all patients. Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | risicogroep | Risk group for non-metastatic rectal cancer
+
Due to the introduction of indication setting for (chemo)radiotherapy (see colorectal cancer guideline), this variable is available from 2015 onwards for non-metastatic rectal cancer. Risk group in non-metastatic rectal cancer is determined at diagnosis based on clinical TNM stage, distance to the mesorectal fascia and extramural invasion.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | tum_budding | Tumour budding present
+
Available from 2019 for T1 tumours (cT1 and/or pT1) treated with local resection. From 2020 onwards, this also includes T1 tumours treated with surgical resection.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | tumregres | Tumour regression
+
Tumour regression is recorded according to the Mandard classification. Available from 2015 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | veneus_invas | Venous invasion
+
Available from 2015. From 2020 onwards, the item venous invasion is available only for patients with a T1 tumour who underwent endoscopic treatment only.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ycm | ycM (TNM)
+
Available from 2015. ycTNM is recorded when radiotherapy and/or systemic therapy is not followed by surgery, to capture the clinical response to therapy in a wait-and-see approach or in cases of progression after neoadjuvant radiotherapy and/or systemic therapy. When it is clear at the start of treatment that radiotherapy and/or systemic therapy is palliative, ycTNM is not recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | ycn | ycN (TNM)
+
Available from 2015. ycTNM is recorded when radiotherapy and/or systemic therapy is not followed by surgery, to capture the clinical response to therapy in a wait-and-see approach or in cases of progression after neoadjuvant radiotherapy and/or systemic therapy. When it is clear at the start of treatment that radiotherapy and/or systemic therapy is palliative, ycTNM is not recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Tumour data | yct | ycT (TNM)
+
Available from 2015. ycTNM is recorded when radiotherapy and/or systemic therapy is not followed by surgery, to capture the clinical response to therapy in a wait-and-see approach or in cases of progression after neoadjuvant radiotherapy and/or systemic therapy. When it is clear at the start of treatment that radiotherapy and/or systemic therapy is palliative, ycTNM is not recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | contact_zkh1 | Hospital of first contact regarding malignancy
+
The first hospital visited by the patient for symptoms related to the malignancy, and where, based on that visit, a (suspected) malignancy is determined.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Process data | prechir_cea | Pre-surgical CEA level (µg/L)
+
Available from 2015 through 2023. In 2015, CEA was recorded pre-operatively only. In 2016 and 2017, both pre- and post-operative values were recorded. From 2018 onwards, CEA is recorded pre- and post-operatively only for colorectal cancer stage II and III tumours, and pre-operatively only for stage IV tumours where treatment of a liver metastasis has taken place. If no surgery was performed, the CEA value is included in the variable prechir_cea.
|
||||||||||||||||||||||||||||||||
| Process data | zkh_patnum | Patient number in hospital | ||||||||||||||||||||||||||||||||
| Risk factors | asa | ASA classification
+
Available from 2015. Score as reported pre-operatively by the anaesthetist. If the patient did not undergo surgical treatment, the ASA score reported by the gastroenterologist before the endoscopic procedure is recorded instead.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci | Charlson Comorbidity Index (weighted)
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
||||||||||||||||||||||||||||||||
| Risk factors | cci_aids | AIDS (including HIV) according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_cat | Number of categories according to the Charlson Comorbidity Index
+
The yes/no variables for categories are summarised in cci_cat (0, 1, 2 or more) and cci (weighted score per
Charlson 1987), with some categories counted only once if both occur:
• Cerebrovascular disease and Hemiplegia
• Diabetes and Diabetes with end organ damage
• Mild liver disease and Moderate/severe liver disease
• Any tumour and Metastatic solid tumour
Alternative summary scoring methods may also be used.
Incomplete scores:
From 2019, registration aligns with the Charlson Comorbidity Index. Earlier records may lack complete
category data, leading to some misclassification, noted in the relevant variable.
Note: From 1995 to 2014, comorbidities were recorded only in the southern Netherlands. From 2015, coverage is sometimes national but not for all tumour types or years. Missing variables indicate no comorbidities recorded for that tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_chf | Congestive heart failure according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_collagenosis | Collagenosis according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_copd | Chronic obstructive pulmonary disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_cvd | Cerebrovascular disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_cvd did not include TIA but did include significant carotid stenosis (treated with carotid endarterectomy or carotid desobstruction). As a result, patients may have been incorrectly included or excluded from the cerebrovascular disease category.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_dementia | Dementia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_eod_dm | Diabetes with end-organ damage according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_dm | Diabetes mellitus according to the Charlson Comorbidity Index
+
From 2019 onwards, registration aligns with the Charlson Comorbidity Index For registrations from earlier years, not all categories can therefore be accurately determined. Up to around 2018: Diabetes managed by diet alone was included in the registration.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_mild_liver | Mild liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect category classification and CCI.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_severe_liver | Severe or moderate liver disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: No distinction was made between mild and moderate or severe liver disease. These patients were all included under cci_liver1 instead of cci_liver2. This does not affect cci_cat but does affect classification into categories and the CCI index.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_malignancy | Other malignancy according to the Charlson Comorbidity Index
+
Previous or concurrent invasive/malignant cancers, excluding basal cell and squamous cell carcinomas of the skin, where the initial diagnosis occurred between five years before and 30 days after the diagnosis of this tumou
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_metastatic | Other metastatic solid tumour according to the Charlson Comorbidity Index
+
Previous or synchronous metastatic cancer diagnosed up to 30 days after the diagnosis of this tumour. The NCR does not have complete registration of metachronous metastases. For many tumour types, these have only been recorded systematically or project-based in recent years, so this variable may sometimes incorrectly show as 0.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_mi | Myocardial infarction according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2012: Cci_mi also included angina pectoris, meaning patients may have been incorrectly included in this variable.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_plegia | Hemiplegia or paraplegia according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_pvd | Peripheral vascular disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_renal | Moderate or severe renal disease according to the Charlson Comorbidity Index
+
Since 2019, registration has been aligned with the Charlson Comorbidity Index. For earlier years, not all categories can be accurately determined. Up to around 2018: Cci_renal also included mild kidney disease, meaning patients may have been incorrectly included in the category moderate or severe renal disease.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | cci_ulcer | Ulcer disease according to the Charlson Comorbidity Index |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Risk factors | perf_stat | WHO performance status before start of therapy
+
WHO performance status before starting therapy. If the Karnofsky score is noted in the medical record, it is converted to WHO score as described in Ma et al. 2010 - Interconversion of three measures of performance status: An empirical analysis. Performance status has been recorded since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chemo | Systemic chemotherapy classified as pre- or post-surgical
+
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local surgical procedures (e.g. polypectomy, excision biopsy, TUR, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chemort | Chemoradiation classified as pre- or post-surgical
+
Both chemotherapy and radiotherapy were part of the treatment, and based on dates/types, this likely represents chemoradiation. The chemotherapy and radiotherapy components are also included in the variables for systemic chemotherapy and radiotherapy.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir | Surgery performed
+
Transanal Endoscopic Microsurgery (TEM) is also included in this surgical variable, as it is performed by a surgeon.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_aanv | Additional surgery performed
+
Additional resections are recorded alongside a specific surgical procedure when extra surgery was performed to achieve a potentially complete resection. This applies in cases of suspected tumour extension or removal of part of another organ or multiple additional organs.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_crm[1-2] | Circumferential resection margin from surgery[1-2]
+
Available from 2009. Until 2020, CRM for the primary tumour and positive lymph nodes was recorded as a single item. From 2020 onwards, the CRM variable refers only to the CRM of the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_dat[1-2] | Date of surgery[1-2] | ||||||||||||||||||||||||||||||||
| Treatment data | chir_hartman[1-2] | Hartmann's resection performed during surgery[1-2]
+
Since Hartmann's procedure has no longer been explicitly recorded in the NCR from 2017 onwards, this item is derived from registration of the absence of an anastomosis or the presence of a stoma without an end date. In some cases, it cannot be determined with certainty whether a Hartmann's procedure was performed. A stoma may be reversed after the registration date, and information on stoma and/or anastomosis may be missing. As a result, Hartmann's procedures may be both under- and over-coded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_int[1-2] | Interval between incidence date and date of surgery (days)[1-2]
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | chir_naadlek[1-2] | Anastomotic leak after surgery[1-2]
+
Available from 2008. Anastomotic leakage or abscess is coded only after resection of the primary tumour. It is recorded only in cases of leakage of bowel contents or abscess formation at the anastomotic site requiring re-operation, radiological drainage, treatment with an endosponge, surgical intervention, or hospital readmission within two months after creation of the anastomosis. An abscess is registered only if explicitly described as such in the medical record. If an abscess is already present at abdominal opening (for example as a result of perforation), the occurrence of subsequent abscesses is not considered relevant.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_opnameduur[1-2] | Length of hospital stay after surgery (days)[1-2] | ||||||||||||||||||||||||||||||||
| Treatment data | chir_rad[1-2] | Radicality of surgery[1-2]
+
Available from 2015.
This item is used for invasive tumours to indicate whether residual tumour is present after a resection aimed at the primary tumour (T). This item does not concern regional lymph nodes or distant metastases.
In determining radicality, only the invasive primary tumour is considered. Any in situ component or lymph nodes in the resection specimen are not included in the assessment of the radicality of the primary tumour.
Microscopically radical resection: When the pathologist reports that the resection margins are free and/or that the procedure was radical, and the surgeon does not indicate in the operative report that residual tumour may have been left behind.
Microscopically irradical resection: When the pathologist reports that the resection margins are not free and/or that the procedure was not radical, and the surgeon does not indicate in the operative report that residual tumour may have been left behind.
Macroscopically irradical resection: When the surgeon states in the operative report that macroscopic residual tumour was left behind due to an incomplete resection of the primary tumour.
This category also applies if the surgeon does not mention this in the operative report, but it is described in the macroscopic section of the pathology report.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_tech[1-2] | Surgical technique[1-2]
+
Available from 2008 onwards, with differentiation for robot-assisted procedures from 2015 onwards.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_toeval | Tumour was an incidental finding during surgery for another indication |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_type[1-2] | Type of surgery[1-2]
+
Transanal Endoscopic Microsurgery (TEM) is also included in this surgical variable, as it is performed by a surgeon.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_urg[1-2] | Urgency of surgery[1-2]
+
Available from 2008 onwards for colon (C18) and rectosigmoid (C19), and from 2015 onwards for rectum (C20) and TEM (123C18). Since 2015, an additional category (urgent) is available.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | chir_zkh[1-2] | Hospital where surgery was performed[1-2] |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | curatief_ther | Therapy with curative intent performed
+
Available from 1989. Therapy with curative intent is not explicitly recorded as such in the Netherlands Cancer Registry (NCR). The occurrence of therapy with curative intent at primary incidence is based on the following assumptions:
For stage 1 tumours, organ and/or local surgery has been performed and/or there is ycT0, ycN0, and ycM0 status (recorded from 2015 onwards).
For stage 2 and 3 tumours, organ surgery has been performed and/or HIPEC has been administered.
For stage 4 tumours, organ surgery has been performed and a metastasectomy and/or ablation of metastases and/or embolization of metastases and/or HIPEC has been performed.
When the stage is unknown, it is assumed that organ surgery has been performed and/or HIPEC has been administered and/or there is ycT0, ycN0, and ycM0 status (recorded from 2015 onwards) and/or local surgery has been performed without evidence of cM1 or pM1.
Curative-intent therapy is assumed for recurrences if the intent of therapy for the primary tumour was curative and organ and/or local surgery has been performed and/or HIPEC treatment has been administered and/or a metastasectomy has been performed and/or ablation of metastases and/or embolization of metastases has been carried out.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | expl_chir | Exploratory surgery performed
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | expl_chir_dat[1-2] | Date of exploratory surgery[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_int[1-2] | Interval between incidence date and date of exploratory surgery (days)[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
||||||||||||||||||||||||||||||||
| Treatment data | expl_chir_uitslag[1-2] | Result of exploratory surgery[1-2]
+
Available from 2009. Exploratory surgery is a procedure initially intended to be curative but discontinued due to inoperability or the patient's clinical condition.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | geen_ther_reden | Reason for not performing tumour-directed therapy
+
Available from 2015. If multiple reasons are recorded, a single reason is registered based on the following hierarchy: comorbidity/performance status > progression/tumour burden/life expectancy/age > refusal/patient preference/social context > low tumour burden/few symptoms > other > unknown.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | hipec | HIPEC performed
+
Available from 2005. For HIPEC procedures from 2019 onwards in hospitals included in the HIPEC registry, the associated cytoreductive surgery is recorded under the variable "type of metastasectomy".
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | hipec_dat1 | Date of first HIPEC
+
Available from 2005. For HIPEC procedures from 2019 onwards in hospitals included in the HIPEC registry, the associated cytoreductive surgery is recorded under the variable "type of metastasectomy".
|
||||||||||||||||||||||||||||||||
| Treatment data | hipec_int1 | Interval between incidence date and date of first HIPEC (days)
+
Available from 2005. For HIPEC procedures from 2019 onwards in hospitals included in the HIPEC registry, the associated cytoreductive surgery is recorded under the variable "type of metastasectomy". The incidence date is defined as the date of first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | hipec_zkh1 | Hospital where first HIPEC was performed
+
Available from 2005. For HIPEC procedures from 2019 onwards in hospitals included in the HIPEC registry, the associated cytoreductive surgery is recorded under the variable "type of metastasectomy".
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | lok_leverther_code[1-3] | Code for local liver therapy[1-3]
+
Available from 2015.
The following therapies are considered local liver therapies:
• Hemihepatectomy
• Wedge excision/segmental liver resection for metastases
• Liver lobectomy for metastases
• Liver wedge resection for metastases
• Liver segmental resection for metastases
• Microwave ablation (MWA) of liver metastases
• Radiofrequency ablation for liver metastases
• Liver metastasectomy using NanoKnife/IRE
• Cryoablation for liver metastases
• Radiotherapy for liver metastases
• Metastasectomy, not otherwise specified, using radiofrequency ablation
• Microwave ablation (MWA) of metastases
Radioembolization and TACE are not considered local liver therapies.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Treatment data | lok_leverther_dat[1-3] | Date of local liver therapy[1-3]
+
Available from 2015.
The following therapies are considered local liver therapies:
• Hemihepatectomy
• Wedge excision/segmental liver resection for metastases
• Liver lobectomy for metastases
• Liver wedge resection for metastases
• Liver segmental resection for metastases
• Microwave ablation (MWA) of liver metastases
• Radiofrequency ablation for liver metastases
• Liver metastasectomy using NanoKnife/IRE
• Cryoablation for liver metastases
• Radiotherapy for liver metastases
• Metastasectomy, not otherwise specified, using radiofrequency ablation
• Microwave ablation (MWA) of metastases
Radioembolization and TACE are not considered local liver therapies.
|
||||||||||||||||||||||||||||||||
| Treatment data | lok_leverther_int[1-3] | Interval incidence date and date of local liver therapy (days)[1-3]
+
Available from 2015.
The following therapies are considered local liver therapies:
• Hemihepatectomy
• Wedge excision/segmental liver resection for metastases
• Liver lobectomy for metastases
• Liver wedge resection for metastases
• Liver segmental resection for metastases
• Microwave ablation (MWA) of liver metastases
• Radiofrequency ablation for liver metastases
• Liver metastasectomy using NanoKnife/IRE
• Cryoablation for liver metastases
• Radiotherapy for liver metastases
• Metastasectomy, not otherwise specified, using radiofrequency ablation
• Microwave ablation (MWA) of metastases
Radioembolization and TACE are not considered local liver therapies.
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | lok_leverther | Local liver therapy performed
+
Available from 2015.
The following therapies are considered local liver therapies:
• Hemihepatectomy
• Wedge excision/segmental liver resection for metastases
• Liver lobectomy for metastases
• Liver wedge resection for metastases
• Liver segmental resection for metastases
• Microwave ablation (MWA) of liver metastases
• Radiofrequency ablation for liver metastases
• Liver metastasectomy using NanoKnife/IRE
• Cryoablation for liver metastases
• Radiotherapy for liver metastases
• Metastasectomy, not otherwise specified, using radiofrequency ablation
• Microwave ablation (MWA) of metastases
Radioembolization and TACE are not considered local liver therapies.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | lok_leverther_zkh[1-3] | Hospital where local liver therapy was performed[1-3]
+
Available from 2015.
The following therapies are considered local liver therapies:
• Hemihepatectomy
• Wedge excision/segmental liver resection for metastases
• Liver lobectomy for metastases
• Liver wedge resection for metastases
• Liver segmental resection for metastases
• Microwave ablation (MWA) of liver metastases
• Radiofrequency ablation for liver metastases
• Liver metastasectomy using NanoKnife/IRE
• Cryoablation for liver metastases
• Radiotherapy for liver metastases
• Metastasectomy, not otherwise specified, using radiofrequency ablation
• Microwave ablation (MWA) of metastases
Radioembolization and TACE are not considered local liver therapies.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_dat[1-3] | Date of local resection performed by a gastroenterologist[1-3]
+
Starting from incidence year 2019, every (diagnostic) polypectomy must be coded, even if it is followed by a more extensive procedure, such as a hemicolectomy. The same applies to other endoscopic treatments such as ESD, EMR, and FTR. This variable largely includes resections performed by a gastroenterologist (MDL specialist), with the exception of ablations (these are performed by an interventional radiologist).
The category "ablation" includes thermoablation, RFA, and MWA of the primary tumor. The category "local tumour destruction" includes local tumour destruction, photodynamic therapy, electrocauterization, cryosurgery, laser coagulation, and Nanoknife/IRE.
Because Transanal Endoscopic Microsurgery (TEM) is performed by a surgeon, this procedure does not fall under this variable but under the variable "surgery" ("chir").
|
||||||||||||||||||||||||||||||||
| Treatment data | mdl_res_enbloc[1-3] | Polyp removed en bloc during local resection performed by a gastroenterologist[1-3]
+
Available from 2019 for the following types of local resection: endoscopic resection/polypectomy, EMR, EID, FTR and ESD.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_int[1-3] | Interval incidence date and date of local resection (days)[1-3]
+
Starting from incidence year 2019, every (diagnostic) polypectomy must be coded, even if it is followed by a more extensive procedure, such as a hemicolectomy. The same applies to other endoscopic treatments such as ESD, EMR, and FTR. This variable largely includes resections performed by a gastroenterologist (MDL specialist), with the exception of ablations (these are performed by an interventional radiologist).
The category "ablation" includes thermoablation, RFA, and MWA of the primary tumor. The category "local tumour destruction" includes local tumour destruction, photodynamic therapy, electrocauterization, cryosurgery, laser coagulation, and Nanoknife/IRE.
Because Transanal Endoscopic Microsurgery (TEM) is performed by a surgeon, this procedure does not fall under this variable but under the variable "surgery" ("chir").
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumor.
|
||||||||||||||||||||||||||||||||
| Treatment data | mdl_res_endo_rad[1-3] | Endoscopic radicality of local resection performed by a gastroenterologist[1-3]
+
Available from 2024 for the following types of local resection: endoscopic resection/polypectomy, EMR, EID, FTR, and ESD.
This item is used for invasive tumours to indicate whether residual tumour is present after a resection aimed at the primary tumour (T). This item does not concern regional lymph nodes or distant metastases.
In determining radicality, only the invasive primary tumour is considered. Any in situ component or lymph nodes in the resection specimen are not included in the assessment of the item "radicality of the primary tumour."
Microscopically radical resection: when the pathologist indicates that the resection margins are clear and/or that the procedure has been radical, and the gastroenterologist does not indicate in the endoscopy report that residual tumour may have been left behind. If the resection margin is 0.1 mm, it is coded as R0.
Microscopically irradical resection: when the pathologist indicates that the resection margins are not clear and/or that the procedure has not been radical, and the gastroenterologist does not indicate in the endoscopy report that residual tumour may have been left behind. If the resection margin is < 0.1 mm, it is coded as R1, provided there is no macroscopically irradical resection.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_rad[1-3] | Radicality of local resection performed by a gastroenterologist[1-3]
+
Available from 2019 through 2023 for the following types of local resection: endoscopic resection/polypectomy, EMR, EID, FTR, and ESD
Note: radicality here is based on a cutoff of 1 mm instead of 0.1 mm.
Starting in 2024, you can use mdl_res_endo_rad, which does apply the 0.1 mm cutoff.
This item is used for invasive tumours to indicate whether residual tumour is present after a resection aimed at the primary tumour (T). This item does not concern regional lymph nodes or distant metastases.
In determining radicality, only the invasive primary tumour is considered. Any in situ component or lymph nodes in the resection specimen are not included in the assessment of the item "radicality of the primary tumour."
Microscopically radical resection: when the pathologist indicates that the resection margins are clear and/or that the procedure has been radical, and the gastroenterologist does not indicate in the colonoscopy report that residual tumour may have been left behind.
Microscopically irradical resection: when the pathologist indicates that the resection margins are not clear and/or that the procedure has not been radical, and the gastroenterologist does not indicate in the colonoscopy report that residual tumour may have been left behind.
Macroscopically irradical resection: when the gastroenterologist indicates in the resection report that macroscopic residual tumour remains due to an incomplete resection of the primary tumour. If the gastroenterologist does not indicate this in the colonoscopy report, but it is described in the macroscopic section of the pathology report, it is also classified as macroscopically irradical.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res | Local resection performed by a gastroenterologist
+
Starting from incidence year 2019, every (diagnostic) polypectomy must be coded, even if it is followed by a more extensive procedure, such as a hemicolectomy. The same applies to other endoscopic treatments such as ESD, EMR, and FTR. This variable largely includes resections performed by a gastroenterologist (MDL specialist), with the exception of ablations (these are performed by an interventional radiologist).
The category "ablation" includes thermoablation, RFA, and MWA of the primary tumor. The category "local tumour destruction" includes local tumour destruction, photodynamic therapy, electrocauterization, cryosurgery, laser coagulation, and Nanoknife/IRE.
Because Transanal Endoscopic Microsurgery (TEM) is performed by a surgeon, this procedure does not fall under this variable but under the variable "surgery" ("chir").
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_rm[1-3] | Resection margin of local resection performed by a gastroenterologist[1-3]
+
Available from 2019 through 2023 for the following types of local resection: endoscopic resection/polypectomy, EMR, EID, FTR, and ESD.
The smallest resection margin is recorded; this may be basal (in depth) or mucosal (lateral margins).
Additional meaning of value 20: no residual tumour after previous polypectomy/EMR/ESD/FTR (maximum distance).
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_type[1-3] | Type of local resection performed by a gastroenterologist[1-3]
+
Starting from incidence year 2019, every (diagnostic) polypectomy must be coded, even if it is followed by a more extensive procedure, such as a hemicolectomy. The same applies to other endoscopic treatments such as ESD, EMR, and FTR. This variable largely includes resections performed by a gastroenterologist (MDL specialist), with the exception of ablations (these are performed by an interventional radiologist).
The category "ablation" includes thermoablation, RFA, and MWA of the primary tumor. The category "local tumour destruction" includes local tumour destruction, photodynamic therapy, electrocauterization, cryosurgery, laser coagulation, and Nanoknife/IRE.
Because Transanal Endoscopic Microsurgery (TEM) is performed by a surgeon, this procedure does not fall under this variable but under the variable "surgery" ("chir").
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | mdl_res_zkh[1-3] | Hospital where local resection was performed by a gastroenterologist[1-3]
+
Starting from incidence year 2019, every (diagnostic) polypectomy must be coded, even if it is followed by a more extensive procedure, such as a hemicolectomy. The same applies to other endoscopic treatments such as ESD, EMR, and FTR. This variable largely includes resections performed by a gastroenterologist (MDL specialist), with the exception of ablations (these are performed by an interventional radiologist).
The category "ablation" includes thermoablation, RFA, and MWA of the primary tumor. The category "local tumor destruction" includes local tumor destruction, photodynamic therapy, electrocauterization, cryosurgery, laser coagulation, and Nanoknife/IRE.
Because Transanal Endoscopic Microsurgery (TEM) is performed by a surgeon, this procedure does not fall under this variable but under the variable "surgery" ("chir").
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_chir | Surgery targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_rt_code | Code for radiotherapy targeting metastases
+
This variable indicates the organ targeted by radiotherapy.
|
||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_code[1-3] | Code for surgery targeting metastases[1-3]
+
If multiple identical treatments are administered on the same day, only the first is recorded.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_rt_dat | Date of radiotherapy targeting metastases | ||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_dat[1-3] | Date of surgery targeting metastases[1-3] | ||||||||||||||||||||||||||||||||
| Treatment data | meta_rt_int | Interval between incidence date and date of radiotherapy targeting metastases | ||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_int[1-3] | Interval between incidence date and date of surgery targeting metastases (days)[1-3] | ||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_rad[1-3] | Radicality of metastasis-directed surgery[1-3]
+
Available from 2015.
The radicality of the performed operation/ablation is coded, regardless of whether (untreated) metastases remain.
In the case of multiple identical treatments performed on the same day, only the first treatment is recorded. If multiple wedge excisions are performed on the same day and there is variation in radicality, the worst radicality is coded.
Microscopically radical resection: >1 mm
Microscopically irradical resection: =1 mm
Macroscopically irradical resection
Radicality is not recorded for all types of surgery aimed at metastases.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_rt | Radiotherapy targeting metastases performed |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | meta_rt_zkh | Hospital where radiotherapy targeting metastases was performed | ||||||||||||||||||||||||||||||||
| Treatment data | meta_chir_zkh[1-3] | Hospital where surgery targeting metastases was performed[1-3] |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | orgsparend | Organ-preserving therapy performed
+
Organ-preserving therapy includes patients treated with radiotherapy and/or TEM, without surgical bowel resection.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | overig_leverther_code[1-3] | Code for other liver therapy[1-3]
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | overig_leverther_dat[1-3] | Date of other liver therapy[1-3]
+
Available since 2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | overig_leverther_int[1-3] | Interval incidence date and date of other liver therapy (days)[1-3]
+
Available since 2015. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | overig_leverther | Other liver therapy performed
+
Available from 2015. Other liver therapies include liver-directed treatments that are not classified as local liver therapy. These include TACE (transarterial chemoembolisation) for liver metastases and transarterial radioembolisation for liver metastases.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | overig_leverther_zkh[1-3] | Hospital where other liver therapy was performed[1-3]
+
Available since 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | postchir_cea | Post-surgical CEA level (µg/L)
+
Available from 2015 through 2023. In 2015, CEA was recorded pre-operatively only. In 2016 and 2017, both pre- and post-operative values were recorded. From 2018 onwards, CEA is recorded pre- and post-operatively only for colorectal cancer stage II and III tumours, and pre-operatively only for stage IV tumours where treatment of a liver metastasis has taken place. If no surgery was performed, the CEA value is included in the variable prechir_cea.
|
||||||||||||||||||||||||||||||||
| Treatment data | prechir_ther_type | Type of preoperative therapy
+
Radiotherapy: This refers to radiotherapy directed at the primary tumour. In the NCR, specific codes are used for internal radiotherapy and intra-operative radiotherapy. In the past, specific codes were applied for several years for short-course radiotherapy and chemoradiotherapy; however, this classification must largely be derived from the start and end dates of radiotherapy and, where applicable, chemotherapy. The intent of radiotherapy (curative, palliative, symptom relief) is not recorded. For this variable, the following assumptions have been made:
-Chemoradiotherapy: Duration of radiotherapy longer than 7 days with overlap in dates with chemotherapy. If the dates of radiotherapy and chemotherapy are missing and both radiotherapy and chemotherapy were administered pre-operatively, this is also considered chemoradiotherapy.
-Short-course radiotherapy: Duration of radiotherapy longer than 1 day and shorter than 10 days.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | respons_dat | Date of response assessment
+
Available from 2016. Recorded for patients receiving systemic therapy (excluding maintenance medication). At diagnosis, this is recorded only for M1 tumours. Where multiple response assessments were available, the best response was recorded.
|
||||||||||||||||||||||||||||||||
| Treatment data | respons_int | Interval incidence date and date of response assessment (days)
+
Available from 2016. Recorded for patients receiving systemic therapy (excluding maintenance medication). At diagnosis, this is recorded only for M1 tumours. Where multiple response assessments were available, the best response was recorded. The incidence date is defined as the date of first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | respons_uitslag | Result of response assessment
+
Available from 2016. Recorded for patients receiving systemic therapy (excluding maintenance medication). At diagnosis, this is recorded only for M1 tumours. Where multiple response assessments were available, the best response was recorded.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | rt | Radiotherapy classified as pre- or post-surgical
+
This variable refers to radiotherapy targeting the primary tumour.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | rt_dosis[1-2] | Total radiotherapy dose (Gy)[1-2]
+
Refers to radiotherapy targeting the primary tumour. In principle, the delivered dose has been recorded. If it could not be verified whether the treatment plan was executed without modification, the planned dose was recorded. Available for the period 2015-2019.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | rt_stop_int[1-2] | Interval between incidence date and end date of radiotherapy (days)[1-2]
+
Refers to radiotherapy targeting the primary tumour. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour
|
||||||||||||||||||||||||||||||||
| Treatment data | rt_start_int[1-2] | Interval between incidence date and start date of radiotherapy (days)[1-2]
+
Refers to radiotherapy targeting the primary tumour. The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | rt_startdat[1-2] | Start date of radiotherapy[1-2]
+
Refers to radiotherapy targeting the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | rt_stopdat[1-2] | End date of radiotherapy[1-2]
+
Refers to radiotherapy targeting the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | rt_type[1-2] | Type of radiotherapy[1-2]
+
Radiotherapy: This refers to radiotherapy directed at the primary tumour. In the NCR, specific codes are used for internal radiotherapy and intra-operative radiotherapy. In the past, specific codes were applied for several years for short-course radiotherapy and chemoradiotherapy; however, this classification must largely be derived from the start and end dates of radiotherapy and, where applicable, chemotherapy. The intent of radiotherapy (curative, palliative, symptom relief) is not recorded. For this variable, the following assumptions have been made:
-Chemoradiotherapy: Duration of radiotherapy longer than 7 days with overlap in dates with chemotherapy. If the dates of radiotherapy and chemotherapy are missing and both radiotherapy and chemotherapy were administered pre-operatively, this is also considered chemoradiotherapy.
-Short-course radiotherapy: Duration of radiotherapy longer than 1 day and shorter than 10 days.
-Other radiotherapy: Duration of radiotherapy is 1 day or longer than 14 days. This category also includes radioembolisation.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | stent | Stent placed
+
Available from 2015.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | stent_dat[1-4] | Date of stent placement[1-4]
+
Available from 2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | stent_int[1-4] | Interval between incidence date and date of stent placement (days)[1-4]
+
Available since 2015. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | stoma | Stoma created
+
Available since 2015 as treatment of the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | stoma_code[1-4] | Code for stoma[1-4]
+
Available since 2015 as treatment of the primary tumour.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | stoma_dat[1-4] | Date of stoma formation[1-4]
+
Available from 2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | stoma_def[1-4] | Permanent stoma created[1-4]
+
Available since 2015 as treatment of the primary tumour. A stoma recorded as permanent in the Netherlands Cancer Registry (NCR) may still have been reversed after the registration date.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | stoma_int[1-4] | Interval incidence date and date of stoma formation (days)[1-4]
+
Available from 2015.
|
||||||||||||||||||||||||||||||||
| Treatment data | stoma_type[1-4] | Type of stoma[1-4]
+
Available from 2015 to 2023.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | syst_code | Code for systemic therapy
+
Systemic therapies in the NCR are coded using the Anatomical Therapeutic Chemical (ATC) classification system. Recording of systemic therapy is not always specific; before 2015, non-specific codes were used more frequently.
|
valuelist
+
the table shows a selection of 12 values
|
|||||||||||||||||||||||||||||||
| Treatment data | syst_start_int | Interval between incidence date and start date of systemic therapy (days)
+
The incidence date is defined as the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_stop_int | Interval between incidence date and end date of systemic therapy (days)
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date. The incidence date is the date of the first histological or cytological confirmation of the primary tumour.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_kuren | Number of systemic therapy cycles |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | syst_startdat | Start date of systemic therapy | ||||||||||||||||||||||||||||||||
| Treatment data | syst_stopdat | End date of systemic therapy
+
The end date of chemotherapy is the day the final cycle is completed. If this date is unknown, the start date of the last cycle may be recorded as the end date.
|
||||||||||||||||||||||||||||||||
| Treatment data | syst_zkh | Hospital where systemic therapy was administered |
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | t1_ther_type | Type of therapy for T1 tumours
+
Treatment of T1 tumours is categorised. In this variable, Transanal Endoscopic Microsurgery (TEM) is classified as local excision rather than surgical resection, unlike in the chir_type variable.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | target | Systemic targeted therapy classified as pre- or post-surgical
+
This variable refers to systemic targeted therapy, including immunotherapy.
Determination of pre- and post-surgical therapy is based on the chronological order of procedures in the NCR. The first surgical resection is used as the reference point. Local procedures (e.g. tumour destruction, excision biopsy, photodynamic therapy, electrocautery, cryosurgery, radiofrequency ablation) are excluded from this determination.
|
valuelist
+
|
|||||||||||||||||||||||||||||||
| Treatment data | tumgericht_ther | Tumour-directed therapy performed
+
Tumour-directed therapy is defined as one or more treatments targeting the primary tumour and/or metastasis(es). If only supportive treatments are given (such as stoma formation) or if treatment is unknown, this is not considered tumour-directed therapy.
|
valuelist
+
|